Aventis CFC-Free Nasacort HFA Approved
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved Aventis'Nasacort HFA (triamcinolone acetonide) for the treatment of nasal symptoms of seasonal and perennial allergic rhinitis in patients six years of age and older April 7
You may also be interested in...
GlaxoSmithKline Flovent HFA Clears FDA
The CFC-free version of Flovent is approved for asthma in patients 12 years and older. The drug is the second HFA nasal steroid available.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.